The capacity to diagnose, stage and treat cancers from a single technological platform is very attractive in cancer management. Referred to as “targeted management”, this approach underscores the importance of identifying non responders as well as those patients who can be expected to respond positively to our C-series peptides. Soricimed is developing a diagnostic suite including imaging, biopsies and blood tests.
Using the ability of our peptides to bind strongly to TRPV6 channels, we have deployed detectable tags on the peptide to use imaging protocols (fluorescence and MRI) to detect TRPV6-rich human ovarian and prostate tumours in mouse xenografts. The scanning protocols, we are developing will also allow monitoring changes in tumore size during a course of treatment.
By measuring the amount of TRPV6 in biopsies with immunohistochemistry we are able to differentiate Stage I ovarian cancer from healthy tissue, a feature that may lead us to a reliable early detection capability for these cancers.
As the entry point to this suite of diagnostics/prognostics, we can detect TRPV6 overproduction in Stage I ovarian, breast and prostate cancers using a blood sample.
A fluorescent marker attached to our diagnostic drug detects ovarian tumours.